24th Apr 2026 15:49
24th April 2026
All Active Asset Capital Limited
('AAA' or 'the Company')
Re-pricing and extension of convertible loan notes
Significant new committed funding
Following its announcement on 12th November 2025, AAA, the technology holding company, provides an update covering the re-pricing and extension of convertible loan notes, significant new committed funding and an offer open to all shareholders to invest in the extended convertible loan note on the revised terms.
Extension and re-pricing of convertible loan notes
The holders of convertible loan notes, dated 19 August 2025 ('CLN1') and 10 November 2025 ('CLN2'), have passed written resolutions to amend the terms of both CLN1 and CLN2 as follows:
- the notes are now convertible into new AAA equity at 0.75p per AAA share (formerly 3p per AAA share),
- the notes now pay no interest (formerly 20% p.a.); and
- the maximum capacity of CLN2 has doubled from £2 million to £4 million.
The revised CLN1 and CLN2 instruments can be found at www.aaacap.com.
As a result of these changes, AAA has received significant demand from new and existing investors for CLN2. CLN2 has already raised over £750,000 and AAA has recently received additional firm new commitments for almost £2 million of investment. Conversations with other existing and prospective investors are ongoing and encouraging.
Offer to all eligible shareholders to subscribe in CLN2
CLN2 is available to all eligible AAA shareholders, who may apply for as much of CLN2 as they wish. All eligible shareholders may, at a minimum, follow their pro rata entitlements to invest in CLN2. Subject to demand, shareholders may be scaled back so that, at a minimum, they receive their pro rata entitlement. If existing shareholders do not subscribe for CLN2's total £4 million capacity, any remaining capacity may be offered to other investors on the same terms.
The deadline for receipt of applications for the revised CLN2 is 11 a.m. on Friday 29th May 2026. The revised CLN2 instrument, an application form, and details of how to apply for CLN2 are available at www.aaacap.com.
Use of new CLN2 funds
Following investment from the previously received proceeds of CLN1 and CLN2, AAA's stake in Sentiance will increase to a majority equity holding of 53%. AAA intends to use the additional proceeds received from the extended CLN2 primarily to subscribe for further additional equity in Sentiance. Any balance of funds raised from CLN2 will be used to finance AAA's working capital requirements.
AAA currently has 2,241,361,403 shares in issue. Assuming CLN1 is converted in full and all £4 million of CLN2 is subscribed for and subsequently converted, AAA will have 3,041,361,403 shares in issue.
AAA intends to issue audited accounts by the end of June 2026 and then hold an AGM at which the Company will seek, amongst other things, shareholder approval for authority to issue shares to enable the conversion of CLN1 and CLN2 into new AAA equity.
Sentiance
Sentiance has continued to build on the commercial progress delivered in 2025 and has made an encouraging start to 2026. This new funding will allow Sentiance to take advantage of the pipeline of contracts and ongoing negotiations it has with some of the world's largest companies.
AAA will issue a separate announcement detailing developments at Sentiance and plans for the future in due course.
For further information:
All Active Asset Capital Limited
James Normand, ChairmanColin McQuade, Executive Director
www.aaacap.com
Burson Buchanan (Financial PR)
Helen Tarbet / Toto Berger
t: +44 (0)20 7466 5000
Important notice
CLN2 is not open to shareholders in the following restricted jurisdictions: the United States, Canada, Australia, Japan, New Zealand, the Republic of South Africa and any other jurisdiction where the extension or availability of the offer (and any other transaction contemplated thereby) would constitute a violation of the relevant laws and/or regulations of that jurisdiction, or where local laws and/or regulations may result in a significant risk of civil, regulatory or criminal exposure, or would result in a requirement to comply with any governmental or other consent or any registration, filing or other formality which the Company regards as unduly onerous.